Noxopharm Ltd. · ASX:NOX
Noxopharm — 2017 ASX Growth Series Conference (Singapore)
24 slides from Noxopharm's conference presentation, Aug 8, 2017
Slide 1: Noxopharm posts corporate presentation ahead of conference
For personal use only Date 8 August 2017 Sydney, Australia NOXOPHARM POSTS CORPORATE PRESENTATION ASX: NOX AHEAD OF CONFERENCE Noxopharm Limited Presentation at Singapore Investor Conference ABN 50 608 966 123 Review of first year of operation Registered Office: Suite 1 Level 6 Sydney, 8 August
Slide 2: Forward-looking statements
known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assuranc
Slide 3: Corporate Presentation August 2017
For personal use only ASX: NOX Corporate Presentation August 2017 1
Slide 4: Objective: oncology
Objective 1 For personal use only To bring ONCOLOGY to market by 2022 a drug (NOX66) that: 🔵 sensitises most forms of cancer to radiotherapy and chemotherapy 🔵 delivers improved survival outcomes for most cancer patients 🔵 becomes a standard-of-care drug in cancer therapy 2
Slide 5: Based on the ability of NOX66
For personal use only BasedONCOLOGY on the ability of NOX66 ….. to increase the cancer cell-killing ability of 🔵 standard cytotoxic chemotherapy drugs by >2000x 🔵 radiotherapy by 10x ….. without affecting healthy cells. 3
Slide 6: Objective: non-oncology drug pipeline
Objective 2 For personal use only ONCOLOGY To develop a pipeline of non-oncology drugs, capable of crossing into the brain, with first-in-class activity against a number of common community diseases/disorders of significant unmet 4
Slide 7: Proprietary LIPROSE drug delivery technology platform
For personal use only BasedONCOLOGY on the proprietary LIPROSE® drug delivery technology platform…. enabling certain classes of drugs to cross the blood- brain barrier 5
Slide 8: NOX66. Current status
NOX66. Current status ….. For personal use only 🔵 First-in-human study • ONCOLOGY Commenced April 2017 (Phase 1b/2a) • Late-stage solid cancers. Safety/efficacy in 16 patients/7 month treatment course • No safety issues to date: NOX66 alone or in combination therapy with chemotherapy (carboplatin)…
Slide 9: NOX66. Aim of current Phase 1/2 program
NOX66. Aim of current Phase 1/Phase 2 program.… For personal use only to identify clinical indication for registration study Potential indications: ONCOLOGY 🔵 Direct radio-sensitisation → complete remission of irradiated lesions in metastatic, castrate-resistant prostate cancer or NSCLC receiving…
Slide 10: NOX66. Opportunity for significant disruption of standard practices
NOX66. Opportunity for significant disruption of For personal use only standard practices in cancer therapy … 🔵 Improved response rates ONCOLOGY Meaningful response rates to radiotherapy and chemotherapy in late-stage cancers currently unresponsive to any therapies 🔵 Allow palliative (less toxic)…
Slide 11: Anticipated reporting: first-in-human study
Anticipated reporting: first-in-human study For personal use only Matrix of 4 end-points based on drug Study NOX66.001 dosage and 3- and 6-month scans v Combination NOX66 + carboplatin 400 mg/AUC4 400 mg/AUC6 v Dose-escalation • NOX66: 400 mg and 800 mg mid-Oct 2017 mid-Jan 2018 • Carboplatin: AUC4
Slide 12: Anticipated reporting: current clinical program
Anticipated reporting: current clinical program For personal use only 2017 2018 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 STUDY 2. First patient STUDY 2. Interim STUDY 2. Final STUDY 3. First patient STUDY 3. Interim STUDY 3. Final STUDY 4. First patient STUDY 4. Interim STUDY 4. Final STUDY 2. Late-stage prostate ca
Slide 13: NOX66 registration (Phase 3) study timetable
NOX66 For personal use only Registration (Phase 3) study timetable 2017 2018 2019 2020 Phase 3 Phase 3 Proof-of-concept data Confirmation commences concludes of final trial Guidance on final design clinical target Approval to commence Phase 3 study 11
Slide 14: NOX66 registration study considerations
NOX66 For personal use only Registration study considerations ….. 🔵 Radiotherapy studies relatively short: 2-3 weeks treatment; scans at 3 and 6 ONCOLOGY months; estimated duration = 24 months 🔵 Multi-national trial: US, UK, EC, CIS, AUSTRALIA, HK 🔵 CRO and Data Manager appointed 🔵 Aim to seek…
Slide 15: Intellectual Property strategy
Intellectual Property strategy ….. For personal use only 🔵 Global Patent Attorneys ONCOLOGY 🔵 PCT patent application strategy; selected territories with > 90% of global anti-cancer drug sales 🔵 Patent applications filed on LIPROSE ® technology/method of administration/use 🔵 2nd generation…
Slide 16: Manufacturing strategy
Manufacturing strategy ….. For personal use only ONCOLOGY 🔵 API (idronoxil) to be manufactured by Indian CMO: GMP scale-up under development 🔵 Final dosage form to be manufactured by Australian CMO: dedicated pilot plant under development (Melbourne) for manufacture of clinical trials batches 🔵…
Slide 17: Commercialisation strategy
Commercialisation strategy ….. For personal use only ONCOLOGY 🔵 NOXOPHARM to undertake registration studies and regulatory submissions in major territories 🔵 Out-licence for major territories (North America, EC, UK, Japan) 🔵 Marketing partnerships in certain territories (China, Russia, CIS) 🔵…
Slide 18: Execution strategy
Execution strategy ….. For personal use only 🔵 Exoperienced team in place to execute all key work streams ONCOLOGY 🔵 Clinical development, medical affairs, regulatory affairs and manufacturing, all headed by experienced personnel with large pharma experience 🔵 Medical Advisor (part-time) is high…
Slide 19: Board of directors
Board of directors ……….. For personal use only Peter Marks BEc LLB MBA Dr Graham Kelly BSc BVSc PhD Dr Ian Dixon MBA, PhD Chairman of the Board Managing Director & CEO Non-Executive Director Non-Executive Director Executive Director 17
Slide 20: Senior Management
Senior Management ……….. For personal use only CEO Ian Minns Ron Sinani Dr Phillip Coghlan Dr Frederic Delebeque Dr Benny Evison Director, Clinical Director, Regulatory Director, Manager, Pre-Clinical Manager, Pre-Clinical Development & Affairs Manufacturing (Oncology) (Non-Oncology) Medical Affairs
Slide 21: Key Messages
For personal use only Key Messages WE EXPECT TO KNOW BY END OF 2017 OF THE SUCCESS OF OUR MISSION WE AIM TO BE IN A REGISTRATION STUDY BY END OF 2018 WE AIM TO HAVE MARKETING APPROVAL BY 2022 A SUCCESSFUL OUTCOME IS A MAJOR SHARE OF THE $100 BILLION ONCOLOGY DRUG MARKET REALISTIC POTENTIAL TO BECOME
Slide 22: Key metrics
Key metrics For personal use only Shares outstanding 85M : 38M free; 47M escrowed (July 2018) $0.70 Other 22.5M options ($0.30) (July 2018) $0.60 $0.50 Market Cap (31.7.2017) $33.4M $0.40 $0.30 $0.20 Cash position AU$ 6.0M IPO (9 Aug 2016) $0.10 9/16 10/16 11/16 12/16 1/17 2/17 3/17 4/17 5/17 6/17 A
Slide 23: Disclaimer
For personal use only Disclaimer • This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or
Slide 24: Contact
For personal use only Contact Dr Graham Kelly Chief Executive Officer graham.kelly@noxopharm.com 22
Noxopharm — 2017 ASX Growth Series Conference (Singapore) on 6ix